134 related articles for article (PubMed ID: 35459877)
21. A 7-Day Decitabine-Included Conditioning Regimen Accelerated Donor Hematopoietic Engraftment while Reduced the Occurrence of Mucositis without Interfering with Prognosis.
Shi YY; Su L; Liu ZY; Cao YG; Chen X; Zhang RL; Liu QZ; Yao JF; Zhai WH; Ma QL; Jiang EL; Han MZ
Chemotherapy; 2023; 68(3):143-154. PubMed ID: 36990070
[TBL] [Abstract][Full Text] [Related]
22. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
[TBL] [Abstract][Full Text] [Related]
23. High-dose busulfan, cyclophosphamide, and etoposide does not improve outcome of allogeneic stem cell transplantation compared to BuCy2 in patients with acute myeloid leukemia.
Farag SS; Bolwell BJ; Elder PJ; Kalaycio M; Lin T; Pohlman B; Penza S; Marcucci G; Blum W; Sobecks R; Avalos BR; Byrd JC; Copelan E
Bone Marrow Transplant; 2005 Apr; 35(7):653-61. PubMed ID: 15711571
[TBL] [Abstract][Full Text] [Related]
24. Impact of treatments before allogeneic hematopoietic stem cell transplantation in patients with higher-risk myelodysplastic syndrome.
Zhang Y; Liu C; Zhang R; Shi Y; Li X; Yu J; Wan D; Xie X
Leuk Res; 2023 Jan; 124():106997. PubMed ID: 36502583
[TBL] [Abstract][Full Text] [Related]
25. [Clinical outcome of allogeneic hematopoietic stem cell transplantation with FLAG sequential busulfan/cyclophosphamide conditioning regimen for refractory/relapsed acute myeloid leukemia].
Liu W; Li Y; Qiu ZX; Yin Y; Sun YH; Xu WL; Wang Q; Liang ZY; Dong YJ; Wang LH; Cen QN; Wang MJ; Wang WS; Ou JP; Ren HY
Zhonghua Nei Ke Za Zhi; 2018 Aug; 57(8):576-581. PubMed ID: 30060329
[No Abstract] [Full Text] [Related]
26. A Randomized Study Comparing Stem Cell Transplantation Versus Conventional Therapy for Low- and Intermediate-Risk Myelodysplastic Syndromes Patients.
Yu ZP; Ding JH; Sun AN; Ge Z; Chen BA; Wu DP
Stem Cells Dev; 2017 Aug; 26(15):1132-1139. PubMed ID: 28494646
[TBL] [Abstract][Full Text] [Related]
27. Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study.
Liu H; Zhai X; Song Z; Sun J; Xiao Y; Nie D; Zhang Y; Huang F; Zhou H; Fan Z; Tu S; Li Y; Guo X; Yu G; Liu Q
J Hematol Oncol; 2013 Feb; 6():15. PubMed ID: 23394705
[TBL] [Abstract][Full Text] [Related]
28. Low relapse risk in poor risk AML after conditioning with 10-day decitabine, fludarabine and 2 Gray TBI prior to allogeneic hematopoietic cell transplantation.
Cruijsen M; Hilberink JR; van der Velden WJFM; Jansen JH; Bär B; Schaap NPM; de Haan A; Mulder AB; de Groot MR; Baron F; Vellenga E; Blijlevens NNM; Huls G
Bone Marrow Transplant; 2021 Aug; 56(8):1964-1970. PubMed ID: 33824442
[TBL] [Abstract][Full Text] [Related]
29. Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality.
Kashyap A; Wingard J; Cagnoni P; Roy J; Tarantolo S; Hu W; Blume K; Niland J; Palmer JM; Vaughan W; Fernandez H; Champlin R; Forman S; Andersson BS
Biol Blood Marrow Transplant; 2002; 8(9):493-500. PubMed ID: 12374454
[TBL] [Abstract][Full Text] [Related]
30. [Retrospective efficacy analysis of decitabine bridging allogeneic hematopoietic stem cell transplantation on the treatment of myelodysplastic syndrome].
Zheng H; Wang J; Zhou J; Wang P; Fu C; Wu D; Sun A; Qiu H; Jin Z; Han Y; Tang X; Ma X
Zhonghua Xue Ye Xue Za Zhi; 2015 Feb; 36(2):121-4. PubMed ID: 25778887
[TBL] [Abstract][Full Text] [Related]
31. Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen.
Saure C; Schroeder T; Zohren F; Groten A; Bruns I; Czibere A; Galonska L; Kondakci M; Weigelt C; Fenk R; Germing U; Haas R; Kobbe G
Biol Blood Marrow Transplant; 2012 Mar; 18(3):466-72. PubMed ID: 21963618
[TBL] [Abstract][Full Text] [Related]
32. Busulfan-containing conditioning regimens in allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia: A Taiwan observational study.
Wang YH; Tien FM; Tsai CH; Huang HH; Liu JH; Liao XW; Tang JL; Yao M; Ko BS
Cancer Rep (Hoboken); 2022 Mar; 5(3):e1488. PubMed ID: 34196132
[TBL] [Abstract][Full Text] [Related]
33. Reduced BUCY 2 and G-CSF-primed bone marrow associates with low graft-versus-host-disease and transplant-related mortality in allogeneic HSCT.
Leon Rodriguez E; Rivera Franco MM; Perez Alvarez SI
Ann Hematol; 2017 Sep; 96(9):1525-1531. PubMed ID: 28691152
[TBL] [Abstract][Full Text] [Related]
34. Meta-analysis of decitabine pretreatment-based allogeneic hematopoietic stem cell transplantation affecting transplantation-related complications and prognosis in patients with malignant hematological disease.
Li L; Zhao Z; Li X
Cell Mol Biol (Noisy-le-grand); 2023 Dec; 69(14):69-75. PubMed ID: 38279480
[TBL] [Abstract][Full Text] [Related]
35. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
[TBL] [Abstract][Full Text] [Related]
36. Conditioning therapy with N-acetyl-L-cysteine, decitabine and modified BUCY regimen for myeloid malignancies patients prior to allogeneic hematopoietic stem cell transplantation.
Tang Y; Zhang Z; Liu S; Yao Y; Pan T; Qi J; Kang H; Liu Y; Cai C; Zhou M; He X; Hu X; Ma X; Wu D; Han Y
Am J Hematol; 2023 Jun; 98(6):881-889. PubMed ID: 36880836
[TBL] [Abstract][Full Text] [Related]
37. Conditioning Regimens in Allogeneic Hematopoietic Stem Cell Transplantation Do Not Fit All: Adjusting BuCy2 in Mexico to Improve Outcomes in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS).
León-Rodríguez E; Rivera-Franco MM
Int J Hematol Oncol Stem Cell Res; 2022 Oct; 16(4):189-197. PubMed ID: 36883113
[No Abstract] [Full Text] [Related]
38. Allogeneic hematopoietic cell transplantation using fludarabine plus myeloablative busulfan and melphalan confers promising survival in high-risk hematopoietic neoplasms: a single-center retrospective analysis.
Edahiro T; Kawase T; Nagoshi H; Fujino K; Toishigawa K; Miyama T; Mino T; Yoshida T; Morioka T; Hirata Y; Noma M; Fujii T; Nishizawa M; Fukushima N; Ichinohe T
Hematology; 2021 Dec; 26(1):186-198. PubMed ID: 33594942
[TBL] [Abstract][Full Text] [Related]
39. [Progress of research on allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning regimen for treatment of myelodysplastic syndrome - review].
Zhang Z; Li X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):969-74. PubMed ID: 18718102
[TBL] [Abstract][Full Text] [Related]
40. Vorinostat Combined with Busulfan, Fludarabine, and Clofarabine Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia: Long-Term Study Outcomes.
Alatrash G; Saberian C; Bassett R; Thall PF; Ledesma C; Lu Y; Daher M; Valdez BC; Kawedia J; Popat U; Mehta R; Oran B; Nieto Y; Olson A; Anderlini P; Marin D; Hosing C; Alousi AM; Shpall EJ; Rondon G; Chen J; Qazilbash M; Champlin RE; Kebriaei P
Transplant Cell Ther; 2022 Aug; 28(8):501.e1-501.e7. PubMed ID: 35618218
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]